Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

Fifteen-year follow-up from the S0016 trial found over one-third of patients with follicular lymphoma treated with chemoimmunotherapy had no progression.

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

A personal look at choosing to be a caregiver, the challenges faced, and the lessons learned while supporting a sister through years with cancer. It may simply be because I cannot adequately explain ...

Ipsen withdrew tazemetostat worldwide for follicular lymphoma and epithelioid sarcoma after new trial data suggested a less favorable safety profile than previously characterized. SYMPHONY-1 ...

FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with residual invasive disease, with a regulatory decision anticipated in Q3 2026.

We are continuing to see an increase in the incidence of kidney cancer in younger patients over time. Maintaining kidney health involves basic lifestyle choices: avoiding obesity, not smoking, and ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Here are five key takeaways for regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer ...

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...